retatrutide phase 2 trial obesity nejm 2023 results Retatrutide (not yet approved in US but people using anyway) promises even potentially greater weight loss amongst the GLP1 drugs. https://www.nejm .org/doi/full/10.1056/NEJMoa2301972 retatrutide phase 2 trial results

Nat Commun 15:2860

Additionally, while Tirzepatide is highly effective in facilitating substantial weight loss it will be most effective when it is used as one component of a broader medical weight management plan

The advanced liposomal delivery system is designed for optimal absorption, so you get the most from every dose

According to the FDA, Wegovy is indicated for chronic weight management in patients with a body mass index (BMI) of 27 kg/m2 or greater who have at least one weight-related ailment or in patients with a BMI of 30 kg/m2 or greater

however, in response to glucose-induced depolarization, these channels open

NR supplementation has also been investigated in relation to neurodegenerative diseases